Danicopan
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Nocturnal Hemoglobinuria
Conditions
Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
Trial Timeline
Aug 11, 2025 → Mar 10, 2028
NCT ID
NCT06449001About Danicopan
Danicopan is a phase 3 stage product being developed by AstraZeneca for Paroxysmal Nocturnal Hemoglobinuria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06449001. Target conditions include Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06449001 | Phase 3 | Recruiting |
Competing Products
20 competing products in Paroxysmal Nocturnal Hemoglobinuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 41 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| LNP023 | Novartis | Pre-clinical | 23 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 77 |
| iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Pre-clinical | 23 |
| Iptacopan | Novartis | Phase 3 | 77 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 3 | 77 |
| LFG316 + LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Crovalimab | Roche | Phase 3 | 77 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 76 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 51 |
| Humanized anti-Factor Bb monoclonal antibody + Placebo | Sanofi | Phase 1 | 32 |